3SBio Inc.
1530
Kedudukan dalam Saham
#3647
Operating as an investment holding company, 3SBio Inc. specializes in the full... Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
Harga Saham
$1.87
Modal Pasaran
$4.67B
Perubahan (1 hari)
0.83%
Perubahan (1 tahun)
-48.40%
Negara
CN
Perdagangan 3SBio Inc. (1530)
Kategori
Healthcare
Margin Operasi untuk 3SBio Inc. (1530)
Margin Operasi pada October 2026 TTM: 61.16%
Menurut laporan kewangan dan harga saham terkini 3SBio Inc., margin operasi semasa (TTM) ialah 61.16%. Pada akhir 2023, margin operasi syarikat ialah 31.45%.
Sejarah Margin Operasi untuk 3SBio Inc. dari 2012 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Ubah |
|---|---|---|
| 2026 (TTM) | 61.16% | 110.32% |
| 2024 | 29.08% | -7.54% |
| 2023 | 31.45% | 4.24% |
| 2022 | 30.17% | 5.42% |
| 2021 | 28.62% | 9.40% |
| 2020 | 26.16% | 4.14% |
| 2019 | 25.12% | -20.25% |
| 2018 | 31.50% | 1.81% |
| 2017 | 30.94% | -4.77% |
| 2016 | 32.49% | 13.56% |
| 2015 | 28.61% | -14.80% |
| 2014 | 33.58% | 5.46% |
| 2013 | 31.84% | 57.08% |
| 2012 | 20.27% | 0.00% |
Margin Operasi untuk syarikat serupa atau pesaing
| Syarikat | Margin Operasi | Perbezaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -99.37% |
US
|
|
| -149.01% | -102.44% |
US
|
|
| 25.57% | -99.58% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.53% |
NL
|
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.